MAFLD, HCC and the dilemma of (changing) terminology in liver diseases

Article Gastroenterology & Hepatology

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database

Alessandro Vitale et al.

Summary: This study compared patients with MAFLD and non-MAFLD who had hepatocellular carcinoma (HCC) in Italy. It found that the proportion of MAFLD in HCC patients was increasing over time and is expected to surpass non-MAFLD in the future. Despite a later cancer stage at diagnosis, MAFLD HCC patients had a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.

GUT (2023)

Add to Collection

Article Gastroenterology & Hepatology

From NAFLD to MAFLD: Implications of a Premature Change in Terminology

Zobair M. Younossi et al.

Summary: The article discusses the proposal to rename NAFLD to MAFLD, highlighting the shortcomings of the new term and warning that changing the name without a comprehensive understanding may have negative implications for the field. The recommendation is to establish a true international consensus group to assess the impact and consequences of the terminology change and make recommendations based on available evidence to move the field forward.

HEPATOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Methods of Public Health Research - Strengthening Causal Inference from Observational Data

Miguel A. Hernan

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology